SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001636050-19-000085
Filing Date
2019-09-24
Accepted
2019-09-24 17:15:15
Documents
1
Period of Report
2019-09-21

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_156935969903570.html 4  
1 FORM 4 wf-form4_156935969903570.xml 4 4124
  Complete submission text file 0001636050-19-000085.txt   5813
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Issuer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O STEADYMED THERAPEUTICS, INC. 2410 CAMINO RAMON SAN RAMON CA 94583
Business Address
Nassif David W. (Reporting) CIK: 0001636975 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37418 | Film No.: 191111495